TAN Ruijuan,WANG Lidan,DU Mei,et al.Meta-analysis of influential factors for all-cause mortality in patients with carbapenem-resistant Gram-negative bacteria treated with polymyxin B[J].ZHONGGUO YAOFANG,2026,37(07):949-953.
TAN Ruijuan,WANG Lidan,DU Mei,et al.Meta-analysis of influential factors for all-cause mortality in patients with carbapenem-resistant Gram-negative bacteria treated with polymyxin B[J].ZHONGGUO YAOFANG,2026,37(07):949-953.DOI: 10.6039/j.issn.1001-0408.2026.07.21.
Meta-analysis of influential factors for all-cause mortality in patients with carbapenem-resistant Gram-negative bacteria treated with polymyxin B
To systematically evaluate the influential factors for all-cause mortality in patients with carbapenem-resistant Gram-negative bacteria (CR-GNB) treated with polymyxin B.
METHODS
2
PubMed, Embase, the Cochrane Library, Web of Science, Wanfang Data, VIP, CBM and CNKI were searched to collect clinical studies on all-cause death within 30 days or 28 days after treatment with polymyxin B in patients with CR-GNB infection from database establishment to July 2025. After literature screening, data extraction and evaluation of literature quality, meta-analysis was performed using RevMan 5.4 software.
RESULTS
2
A total of 12 studies were included, involving 1 326 patients, among whom 529 patients died, with a mortality rate of 39.89%. Meta-analysis results showed that combined with cardiovascular disease [OR=2.06, 95%CI (1.37, 3.09),
, use of vasoactive drugs [OR=2.90, 95%CI (1.97, 4.27),
P
<0.001
]
, and the occurrence of acute kidney injury (AKI) [OR=2.17, 95%CI (1.41, 3.36),
P
<0.001
]
were risk factors for all-cause mortality in patients with CR-GNB infection treated with polymyxin B. Conversely, an extended duration of polymy
xin B treatment [OR=0.92, 95%CI (0.86, 0.99),
P
=0.03
]
and early administration after CR-GNB infection [OR=0.47, 95%CI (0.25, 0.85),
P
=0.01
]
were protective factors.
CONCLUSIONS
2
Patients with cardiovascular disease, receiving mechanical ventilation or CRRT, having bloodstream infection, multiple-site infection or septic shock, combining with vasoactive drugs, with AKI and increased SOFA scores have a higher risk of all-cause mortality. Conversely, extending the duration of polymyxin B treatment (beyond 7 days) and early administration within 48 hours after confirmed CR-GNB infection can significantly reduce the risk of all-cause mortality.
关键词
Keywords
references
MOURABITI F , JOUGA F , SAKOUI S , et al . Mechanisms,therapeutic strategies,and emerging therapeutic alternatives for carbapenem resistance in Gram-negative bacteria [J ] . Arch Microbiol , 2025 : 58 - 61 .
Antimicrobial Resistance Collaborators . Global burden of bacterial antimicrobial resistance in 2019:a systematic analysis [J ] . Lancet , 2022 , 399 ( 10325 ): 629 - 655 .
YU Z W , HU H D , LIU X F , et al . Clinical outcomes and pharmacokinetics/pharmacodynamics of intravenous polymyxin B treatment for various site carbapenem-resistant Gram-negative bacterial infections:a prospective observational multicenter study [J ] . Antimicrob Agents Chemother , 2025 , 69 ( 4 ): e01824 - e01859 .
STANG A . Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses [J ] . Eur J Epidemiol , 2010 , 25 ( 9 ): 603 - 605 .
JIANG N H , XIE W G , WANG D Y , et al . Early appropriate therapy with polymyxin B reduces the mortality in burn sepsis caused by carbapenem-resistant Gram-negative bacteria:a retrospective analysis [J ] . Eur J Clin Microbiol Infect Dis , 2025 , 44 ( 6 ): 1433 - 1442 .
JIA X D , YIN Z , ZHANG W , et al . The efficacy and influencing factors of polymyxin B in high-level carbapenem-resistant Klebsiella pneumoniae infections [J ] . Infect Drug Resist , 2023 , 16 : 4177 - 4187 .
LI L X , HUANG X H , LIU J X , et al . Efficacy and safety factors related to plasma concentration-optimized polymyxin B therapy in treating carbapenem-resistant Gram-negative bacterial infections in China [J ] . Infect Drug Resist , 2024 , 17 : 3057 - 3071 .
LU Q , LI G H , QU Q , et al . Clinical efficacy of polymyxin B in patients infected with carbapenem-resistant organisms [J ] . Infect Drug Resist , 2021 , 14 : 1979 - 1988 .
KIM T , PARK K H , YU S N , et al . Early intravenous colistin therapy as a favorable prognostic factor for 28-day mortality in patients with CRAB bacteremia:a multicenter propensity score-matching analysis [J ] . J Korean Med Sci , 2019 , 34 ( 39 ): e256 .
YU L L , SHI X P , HUANG J F , et al . A retrospective observational study of the treatment with polymyxin B for liver transplantation recipients infected by multidrug-resistant Gram-negative bacteria [J ] . J Clin Pharm Ther , 2022 , 47 ( 10 ): 1563 - 1569 .
ZHANG X J , QI S Y , DUAN X G , et al . Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections:a real-world multicenter study [J ] . J Transl Med , 2021 , 19 ( 1 ): 431 .
ZHOU S M , LUO X M , CHENG S , et al . Predictive factors for 30-day mortality after polymyxin B treatment of carbapenem-resistant Gram-negative bacilli infections [J ] . Int J Infect Dis , 2025 , 154 : 107844 .
WLAZLO N , VAN GREEVENBROEK M M , CURVERS J , et al . Diabetes in patients with cirrhosis is associated with higher incidence of spontaneous bacterial peritonitis,but not with increased mortality [J ] . Nederlands Tijdschrift Voor Diabetol , 2012 , 10 ( 3 ): 145 .
CHAFRANSKA L , STENHOLT O O , SØRENSEN R H , et al . Predictors for mortality in patients admitted with suspected bacterial infections:a prospective long-term follow-up study [J ] . Am J Emerg Med , 2022 , 56 : 236 - 243 .
QUICKFALL D , LA A , PISANO J , et al . Infections and mortality in ICU patients undergoing continuous renal replacement therapy:a retrospective cohort study [J ] . BMC Nephrol , 2025 , 26 ( 1 ): 321 .
COGLIATI D F , COVINO S , PETRUCCI F , et al . Risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and related mortality in critically ill patients with CRAB colonization [J ] . JAC Antimicrob Resist , 2023 : 96 - 101 .
RIGATTO M H , BEHLE T F , FALCI D R , et al . Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality:a multicentre prospective cohort study [J ] . J Antimicrob Chemother , 2015 , 70 ( 5 ): 1552 - 1557 .
SUN X M , ZHANG Y J , ZHANG L P , et al . Long course of polymyxin B for the treatment of brain abscess caused by carbapenem resistant Acinetobacter baumannii :a case report [J ] . Zhonghua Wei Zhong Bing Ji Jiu Yi Xue , 2021 , 33 ( 11 ): 1370 - 1372 .
LIANG Q Q , HUANG M , XU Z J . Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection [J ] . Braz J Infect Dis , 2019 , 23 ( 1 ): 60 - 65 .
Systematic analysis of population pharmacokinetics of lacosamide
Meta-analysis of the effects of different doses of vitamin D supplementation on maternal and infant outcomes in vitamin D-deficient pregnant women
Compound glutamine enteric-coated capsules in the treatment and prevention of radiotherapy- and chemotherapy-related intestinal dysfunction in patients with malignant tumors: a systematic review
Meta-analysis of the efficacy and safety total glucosides of paeonia in the treatment of systemic lupus erythematosus
系统评价盐酸氨溴索注射液静脉滴注联合雾化吸入治疗新生儿
Related Author
CUI Sai
MENG Nan
WU Huizhen
WU Yin
SHI Xiaoxia
WANG Weina
LI Rui
DU Yaheng
Related Institution
College of Pharmacy, Hebei Medical University
Dept. of Pharmacy, Hebei General Hospital/Hebei Key Laboratory of Clinical Pharmacy
Dept. of Neurological Rehabilitation, Hebei General Hospital
Dept. of Obstetrics, Hengshui Maternal and Child Health Hospital
Dept. of Pharmacy, West China Hospital of Sichuan University